Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Carcinoma 3Fallopian Tube Neoplasms 2Sarcoma 1Renal Insufficiency 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1Congenital Abnormalities 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Temozolomide 30Radiotherapy 23Filgrastim 12Carmustine 12Irinotecan 11Carboplatin 11Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Etoposide 7Surgical Procedures, Operative 6Magnetic Resonance Spectroscopy 6Vincristine 5Peripheral Blood Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclophosphamide 5sargramostim 4motexafin gadolinium 4Topotecan 4Thiotepa 4Paclitaxel 4Melphalan 4Gene Expression Profiling 4Gemcitabine 4Drug Therapy 4Busulfan 4temsirolimus 3etoposide phosphate 3Specimen Handling 3Mass Spectrometry 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Central Nervous System Neoplasms × trebananib × Clear all
NCT01538095 2016-10-03

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

National Cancer Institute (NCI)

Phase 1 Completed
37 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡